MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
July 08, 2022 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
July 07, 2022 07:00 ET
|
MediWound Ltd.
EscharEx Showed Safe, Effective and Rapid Debridement in VLUs and DFUsData Demonstrates EscharEx Reduced Wound Size, Biofilm and Bacterial Burden YAVNE, Israel, July 07, 2022 (GLOBE NEWSWIRE) --...
MediWound to Host a Key Opinion Leader Investor Day on EscharEx
July 05, 2022 16:05 ET
|
MediWound Ltd.
YAVNE, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Names Mr. Tzvi Palash as Chief Operating Officer
June 30, 2022 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
MediWound Announces CEO Transition
May 17, 2022 07:01 ET
|
MediWound Ltd.
Ofer Gonen, current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka, who will join the Board of Directors ...
MediWound Reports First Quarter 2022 Financial Results
May 17, 2022 07:00 ET
|
MediWound Ltd.
Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds On track for NexoBrid BLA resubmission by mid-year Conference Call Begins Today at 8:30 am ET YAVNE,...
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
May 12, 2022 07:00 ET
|
MediWound Ltd.
Study Met Primary and Key Secondary Endpoints with Statistically Significant Results Compared to Control Arms Significant Improvement Across Multiple Measures Over the Current Non-Surgical...
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
May 10, 2022 16:01 ET
|
MediWound Ltd.
YAVNE, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and...
MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
April 12, 2022 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair...
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
March 29, 2022 08:00 ET
|
MediWound Ltd.
Results Highlight the Safety and Efficacy in Hard-to-Heal Wounds SAWC to Take Place in Phoenix, Arizona on April 6-10, 2022 YAVNE, Israel, March 29, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd....